Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma.
Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma.
复制标题
DAB2IP 甲基化的验证及其在预测肾细胞癌预后中的相对意义。
DOI:
10.18632/oncotarget.8971
复制
发表时间:
2016-05-24
期刊:
影响因子:
--
通讯作者:
Luo JH
中科院分区:
文献类型:
--
作者:
Wang ZR;Wei JH;Zhou JC;Haddad A;Zhao LY;Kapur P;Wu KJ;Wang B;Yu YH;Liao B;He DL;Chen W;Margulis V;Hsieh JT;Luo JH
We have recently reported tumor suppressive role of DAB2IP in RCC development. In this study, We identified one CpG methylation biomarker (DAB2IP CpG1) located UTSS of DAB2IP that was associated with poor overall survival in a cohort of 318 ccRCC patients from the Cancer Genome Atlas (TCGA). We further validated the prognostic accuracy of DAB2IP CpG methylation by pyrosequencing quantitative methylation assay in 224 ccRCC patients from multiple Chinese centers (MCHC set), and 239 patients from University of Texas Southwestern Medical Center at Dallas (UTSW set) by using FFPE samples. DAB2IP CpG1 can predict the overall survival of patients in TCGA, MCHC, and UTSW sets independent of patient age, Fuhrman grade and TNM stage (all p<0.05). DAB2IP CpG1 successfully categorized patients into high-risk and low-risk groups with significant differences of clinical outcome in respective clinical subsets, regardless of age, sex, grade, stage, or race (HR: 1.63-7.83; all p<0.05). The detection of DAB2IP CpG1 methylation was minimally affected by ITH in ccRCC. DAB2IP mRNA expression was regulated by DNA methylation in vitro. DAB2IP CpG1 methylation is a practical and repeatable biomarker for ccRCC, which can provide prognostic value that complements the current staging system.
登录
查看更多内容
影响因子:
6.4
作者:
Grasbon-Frodl, Eva M.;Kreth, Friedrich Wilhelm;Kretzschmar, Hans A.
通讯作者:
Kretzschmar, Hans A.
影响因子:
4.8
作者:
Wang, Z;Tseng, CP;Hsieh, JT
通讯作者:
Hsieh, JT
影响因子:
4.8
作者:
Chen, H;Toyooka, S;Hsieh, JT
通讯作者:
Hsieh, JT
影响因子:
4.5
作者:
Schuebel KE;Chen W;Cope L;Glöckner SC;Suzuki H;Yi JM;Chan TA;Van Neste L;Van Criekinge W;van den Bosch S;van Engeland M;Ting AH;Jair K;Yu W;Toyota M;Imai K;Ahuja N;Herman JG;Baylin SB
通讯作者:
Baylin SB
影响因子:
23.4
作者:
Gulati S;Martinez P;Joshi T;Birkbak NJ;Santos CR;Rowan AJ;Pickering L;Gore M;Larkin J;Szallasi Z;Bates PA;Swanton C;Gerlinger M
通讯作者:
Gerlinger M